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INTRO D U C T I O N
Between 1999 and 2017 more than 400,000 people died due
to an opioid-related death from both prescription and illicit
use.1 Opioid overdose can occur as a result of accidental misuse of a legitimate prescription or as a result of intentional
drug abuse, and it is among the most preventable public
health threats facing the United States. Numerous initiatives and strategies have been proposed and implemented
to help with the growing opioid issue. This report aims to
provide insight into programs and products available in the
United States which address mitigation strategies to promote safe and appropriate opioid prescribing.

both prescribers and pharmacists in Rhode Island it is also
suggested to check the PDMP before prescribing or dispensing a benzodiazepine or central nervous system-sedating
medication.2 All 50 states currently utilize a PDMP system.
(Figure 1).
Figure 1. State Specific PDMP Requirements3

PRES C RI P T I O N DR UG M ONI T OR I NG P R OGRA M
(PD M P )
The prescription drug monitoring program (PDMP) is an
electronic database used to track controlled substance prescriptions in each state. This database logs controlled drug
prescription information including location, prescriber, and
payment source. PDMP content, access, and utilization varies from state to state; however, they share the common goal
of tracking the use of potentially abused medications and
utilizing the data to implement positive change. Prescribers and pharmacists access the PDMP to obtain information
about a patient’s past medication history for controlled substances. The information included in a PDMP report allows
for assessment of risks when issuing a new prescription, and
also alerts the healthcare professional to recent prescription opioid use. This information may potentially serve
as a deciding factor regarding opioid issuance, dosage, and
duration of therapy. In Rhode Island, prescribers must check
the PDMP prior to prescribing a controlled substance to a
patient for the first time and if the patient remains on therapy it is recommended to check the PDMP every 3 months.
For pharmacists in Rhode Island, it is recommended that
they check the PDMP before dispensing a controlled prescription to a patient for the first time and every 3 months
thereafter, if the patient remains on long-term therapy. For
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INITIA L OP IOID P RESC RIB ING LIMITS BY STATE
States have begun restricting the total daily amount (mg) of
opioid prescribed and quantities dispensed by pharmacies.
Furthermore, more stringent restrictions have been placed
when the opioid is prescribed for the first time, defined as
the initial fill. The designation of ‘initial fill’ is determined
by review of the PDMP records, and is typically defined by
absence of a prescription for an opioid medication within a
specified amount of time (i.e. preceding 30 or 60 days). Limits range from a specific day supply to certain dosage units
based on morphine milligram equivalents (MMEs), with the
most common being a 7-day limit on initial fill of an opioid
(Figure 2). Currently there are four states with a 3-day supply limit, three states with a 4-day supply limit, three states
with a 5-day supply limit, 29 states with a 7-day supply
limit, one state with a 14-day supply limit and nine states
with no limit. Washington state law limits initial opioid
prescriptions to no more than 30 dosage units and Oregon
does not have a law that limits initial opioid prescriptions;
however, the health authority recommends no more than a
7-day trial. Maine has implemented a 100 MME/day limit,
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Figure 2. State Specific Opioid Prescribing Limits4

Tennessee has implemented a 60 MME/day limit, Nevada
has implemented a 90 MME/day limit, and Nebraska has
implemented a 50 MME/day limit. Rhode Island defines
their initial opioid prescribing limit as 30 MME per day for a
maximum of 20 dosage units.5
Although the states themselves are implementing limits
on initial opioid fills, third-party payers may also limit initial
fills to a pre-determined day supply. For example, Anthem,
Inc. was among the first to limit patient’s first fill of opioids
to a 7-day supply.6 Similarly, in 2018 CVS Caremark® also
placed a 7-day supply limit on opioid prescriptions for an
acute condition in which patients had not received opioids
in the past 90 days.7

NA L O X O N E A C C E S S I B I L I T Y
Pharmacologically, naloxone is a mu-opioid antagonist that
displaces opioids that are bound at mu-opioid receptor sites.
The physiological response to using this drug is immediate reversal of respiratory suppression and it is available in
injectable and intranasal formulations. Almost all states
have enacted Good Samaritan laws which protect citizens
from legal implications when administering naloxone to a
person in need. Good Samaritan laws are vital to protect
both parties to ensure that patients receive access to care
without concern for prosecution. The majority of states
allow pharmacists to dispense naloxone to patients without
a prescription if deemed fit, with the exception of Connecticut, Idaho, Nebraska, and Oregon.8
Eight states require co-prescribing of naloxone when a
patient is prescribed an opioid, and under specific conditions. For example, Arizona requires co-prescribing if the
prescription issued exceeds 90 MME per day.9 In California,
prescribers must offer a prescription for naloxone if the prescription dosage for the patient is 90 or more MMEs per day,
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if the patient is concurrently using an opioid and benzodiazepine, or if the patient is deemed as having an increased risk
for overdose, which could include history of substance use
disorder or returning to a high dose of medication when the
patient is no longer as tolerant to that dose.10 New Mexico
requires a naloxone prescription with any opioid prescription exceeding a 5 day supply.11 In Rhode Island, co-prescribing is mandatory under 3 different scenarios: the patient is
taking 50 or more MME per day, the patient is taking opioid
and benzodiazepine concurrently, or when prescribing an
opioid to a patient who has a history of opioid use disorder.5
Vermont requires co-prescribing for patients on 90 or more
MME per day, or if the patient is using an opioid and benzodiazepine concurrently.12 Virginia requires co-prescribing
if the patient’s daily MME exceeds 120, or if the patient is
using an opioid and benzodiazepine concurrently.13 In Washington, prescribers must provide naloxone prescription when
patient exceeds 50 MME per day.14 Florida requires naloxone
to be co-prescribed when a patient is being treated with a
Schedule II controlled substance for a traumatic injury with
an Injury Severity Score of 9 or greater.15

A B U SE-D ETERRENT F ORMU LATIONS
In 2017, more than 190 million opioid prescriptions were dispensed from outpatient retail pharmacies; however of those,
only about 3.8 million were written for an abuse-deterrent
formulation (ADF).16 There are various mechanisms utilized
to develop abuse-deterrent formulations: physical/chemical barriers, agonist/antagonist combinations, aversion,
delivery systems and new molecular entities or prodrugs.1,17
Through the addition of agents such as gel or microspheres,
physical/chemical barriers make it significantly more difficult to abuse a drug through injecting, chewing, crushing, or snorting. There are currently seven abuse-deterrent
opioids commercially available that utilize a physical/
chemical barrier formulation: Oxycontin®, Xtampza® ER,
Morphabond™ ER, Hysingla™ ER, Arymo™ ER, ZoHydro®
ER and RoxyBondTM IR (Table 1). In a review of 15 pre-market studies, several ADFs showed improvement in endpoint
scores when compared to their non-ADF counterparts. For
example, Hysingla™ ER was shown to have a noticeable
effect on the primary endpoints, drug-liking and likelihood
of taking the drug again, when compared to hydrocodone,
and the same can be said for Embeda® when compared to
morphine sulfate.18
The mechanism of action for drugs that use an agonist/
antagonist formulation is such that the antagonist component of the drug is released only when the drug is tampered with, or taken via a non-oral route. The antagonist
portion would displace the opioid agonist from the receptor,
precipitating a withdrawal syndrome.
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Table 1.
DRUG

FORMULATION

MECHANISM OF ACTION

Oxycontin

Physical/chemical barrier

Oxycodone formulated using high- molecular- weight polyethylene oxide as the tablets outer
coating to resist crushing. Also becomes a viscous gel to resist use via needles/IV.

Xtampza® ER

Physical/chemical barrier

Oxycodone formulated with DETERx® technology, which incorporates oxycodone into fatty acid
and wax microspheres resulting in slow diffusion- controlled drug release.

MorphabondTM ER

Physical/chemical barrier

Morphine sulfate formulated with SentryBondTM technology, which retains extended- release
properties if manipulated and becomes viscous to resist use via needles/IV.

HysinglaTM ER

Physical/chemical barrier

Hydrocodone bitartrate formulated with ResistecTM, which hardens the tablet to increase
difficulty of manipulation and becomes viscous when dissolved.

ArymoTM ER

Physical/chemical barrier

Morphine sulfate formulated using a polymer matrix to make it more difficult to cut, crush, grind
or break.

Embeda®

Agonist/antagonist combo

Morphine sulfate + naltrexone HCl. The naltrexone is stored at core of the pill in a sequestering
membrane and is only released when capsule is manipulated.

ZoHydro® ER

Physical/chemical barrier

A combination of 20% IR and 80% ER hydrocodone bitartrate formulated with BeadTek®, which
forms a viscous gel if capsule is crushed or dissolved.

RoxybondTM IR*

Physical/chemical barrier

Oxycodone formulated with SentryBondTM technology to make release lower and slower when
manipulated. Also becomes viscous to resist use via needles/IV.

®

*First and only immediate release abuse-deterrent formulation

M ED I C A RE PA RT D O P I O I D
OV E RU T I L I Z AT I O N P O L I C Y
In 2019, Medicare implemented the Part D Opioid Overutilization Policy. This policy is primarily focused on encouraging interdisciplinary collaboration and coordination in
order to improve universal patient care across providers.19
The primary areas of the policy include pharmacy alliance
data, drug management programs, day supply limits, and
opioid care coordination alerts.
Pharmacy alliance data has three focal points: prevention
of new cases of opioid overutilization, treatment of existing patients, and proper utilization of data. To prevent new
cases, inappropriate prescribing must be identified, non-opioid treatments must be promoted, and opioid use disorder
diagnoses must be enhanced. When treating existing pain
patients, it has been recommended to offer a broad range of
treatment options and to continuously implement updated
practices. This data enables healthcare professionals to recognize opioid prescribing patterns and to monitor the effectiveness and safety of treatment.20
Drug management programs (DMP) proactively aid the
healthcare professional in identifying patients who may be
at risk for misuse, abuse or potential overdose when prescribed an opioid or benzodiazepine. Once identified, the
Part D plan will contact the prescriber to determine medical
necessity or potential risk for abuse. Medicare also determines if the patient may benefit from the implementation of
a DMP to manage their prescriptions. Three major DMPs are
patient-specific, point-of-sale claim edit (POS), pharmacy
limitation, and prescriber limitation. Once a patient’s insurance performs a case review and gives approval, POS can be
used to limit the amount of frequently abused drugs that
can be dispensed to a patient. Pharmacy limitation requires
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a patient to fill all prescriptions for frequently abused drugs
at a specific pharmacy of their choosing. Prescriber limitation requires a patient to obtain all medications of potential
misuse from a sole provider, and contractual agreements
between prescriber and patient may be utilized.
The most recent Medicare policy also enacted an initial
7-day supply limit for opioid- naïve patients and an opioid
care coordination alert. The goal of a limiting day supply
limit is to reduce long-term opioid use in patients who
initially receive a prescription for treatment of acute pain.
The opioid care coordination alert is intended to advise the
pharmacist to consult the prescriber when a patient’s overall
daily oral morphine equivalence exceeds 90 mg, to confirm
appropriate use.

F D A OP IOID A C TION P LA N
The FDA has recognized opioid abuse, dependence, and
overdose as a public health crisis in the United States. In
response, the Administration unveiled their Opioid Action
Plan in 2016, which sought to establish advisory committees,
propose appropriate regulatory activities and policy development, with goals of improving the science of pain management and fostering communication and collaboration
across fields.
The FDA aimed to establish an expert advisory committee
that would review new opioid drug applications that are not
manufactured as abuse-deterrent formulations. In addition,
a pediatric advisory committee is intended to review and
generate recommendations on labeling of opioids in regards
to the pediatric population.21
Extended-release and long-acting opioid formulations
are currently subject to a Risk Evaluation and Mitigation
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Strategy (REMS) program. The FDA expanded REMS programs to include not only product-specific materials, but
also educational programs in pain management. Training
and education has been expanded to include more members
of the health care team, rather than solely prescribers. Immediate release opioid labeling will expand to include any additional warning and safety information that is available, with
the overall goal of this initiative being to promote safer prescribing practices of immediate release opioid formulations.
The development of ADFs has become a major area of
interest in the pharmaceutical industry. The issue still persists, however, that the currently available ADFs are brand
name products. This may pose a significant financial burden
which limits their access for use. In response to the need to
increase accessibility of opioid ADFs, the FDA has issued
a high priority draft guidance to encourage the approval of
generics.
The availability of naloxone varies from state to state. As
outlined in the FDA’s 2018 Strategic Policy roadmap, overthe-counter (OTC) naloxone is being reviewed to allow for
expanded access.22 States such as Rhode Island have approved
the purchase of OTC naloxone and data from 2016-2018 correlated the reduction in opioid-overdose related deaths to
the increased availability of naloxone during this time.23

CU R REN T U S E OF S T R AT E G I E S
The use of the PDMP remains the most common mitigation strategy in the US. Naloxone accessibility has also
improved; however, further efforts are needed to increase
access across all 50 states. Most states are implementing
prescribing limits on initial opioid prescription fill quantities. Lastly, affordability and further access to ADF products
is needed to aid in combating the opioid crisis. (Figure 3)
While no single approach will be sufficient to mitigate opioid risks while balancing appropriate use, a strategy that
considers multiple possible approaches is needed to improve
the health care landscape regarding opioid safety.
Figure 3. Nationwide Current Implementations of Mitigation Strategies
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